Arndt Vogel· @ArndtVogel · X·· 2 days agoScore90
Body · original
G-HOPE-001 phs-3: Arcotatug tavatecan vs TPC in previously treated G/GEJA: First interim analysis
#ESMO26 #ESMOAmbassadors
🇨🇳🇯🇵, 2600 prescreened, 430 included
👉ORR: 37 vs 7.7%
👉 mPFS: 7.1 vs 3.1 mo
👉 mOS: 10.2 vs 6.9 mo
🧐CLDN-2 ADC, strong signal of efficacy, acceptable safety
@myESMO @ASCO
1800 views · 28 likes · 17 reposts · 0 replies
Conference abstracts
LBA77matched by Proffered paper 1: Gastrointestinal tumour, upper digestive
Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G
https://esmocongress.esmo.orgSource: Arndt Vogel · x.com